MiR-378 suppresses prostate cancer cell growth through downregulation of MAPK1 in vitro and in vivo.
Prostate cancer is one of the biggest health problems for the aging male. To the present, the roles of dysregulated microRNAs in prostate cancer are still unclear. Here, we evaluated the anti-proliferative role of miR-378 in prostate cancer. And, we found that the expression of miR-378 was significantly downregulated in clinical prostate cancer tissues. In vitro assay suggested that overexpression of miR-378-suppressed prostate cancer cell migration and invasion promoted cell apoptosis. Furthermore, we identified and validated MAPK1 as a direct target of miR-378. Ectopic expression of MAPK1 rescues miR-378-suppressed cell migration and invasion. In vivo assay demonstrated that the stably miR-378-overexpressed prostate cancer cells displayed a significantly reduction in tumor growth. Taken together, our data suggested that miR-378 may act as a potential therapeutic target against human prostate cancer.
Department of Urology, The First Affiliated Hospital of China Medical University, Nanjing Street 155#, Shenyang, 110001, Liaoning, China.
Qi-Guang
QG
Chen
Department of Diagnostic Radiology, General Hospital of Shenyang Military Region, Shenyang, Liaoning, China.
Wei
W
Zhou
Department of Oncology, General Hospital of Shenyang Military Region, Shenyang, Liaoning, China.
Tao
T
Han
Department of Urology, The First Affiliated Hospital of China Medical University, Nanjing Street 155#, Shenyang, 110001, Liaoning, China.
Shu-Qi
SQ
Du
Department of Urology, The First Affiliated Hospital of China Medical University, Nanjing Street 155#, Shenyang, 110001, Liaoning, China.
Zhen-Hua
ZH
Li
Department of Urology, The First Affiliated Hospital of China Medical University, Nanjing Street 155#, Shenyang, 110001, Liaoning, China.
Zhe
Z
Zhang
Department of Urology, LiaoNing Cancer Hospital and Institute, Shenyang, Liaoning, China.
Guang-Yi
GY
Shan
Department of Urology, The First Affiliated Hospital of China Medical University, Nanjing Street 155#, Shenyang, 110001, Liaoning, China. kongchuize4081@163.com.
Chui-Ze
CZ
Kong
D000328:Adult; D000368:Aged; D000818:Animals; D017209:Apoptosis / Q000235:genetics; D015153:Blotting, Western; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics; D049109:Cell Proliferation / Q000235:genetics; D015536:Down-Regulation; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics*; D064593:Heterografts; D006801:Humans; D008297:Male; D051379:Mice; D008819:Mice, Nude; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D019950:Mitogen-Activated Protein Kinase 1 / Q000096:biosynthesis* / Q000235:genetics; D011471:Prostatic Neoplasms / Q000235:genetics / Q000473:pathology*; D060888:Real-Time Polymerase Chain Reaction
C526012:MIRN378 microRNA, human; D035683:MicroRNAs; C535150:MAPK1 protein, human; D019950:Mitogen-Activated Protein Kinase 1
MAPK1; Prostate cancer; miR-378; microRNA